INTRODUCTION
Liver transaminases are the biochemical markers of hepatocyte affection by an inflammatory process. Accidental discovery of isolated elevation of liver transaminases in asymptomatic patients is not uncommonly met with in the daily practice in the setting of routine or periodic self-health screening, routine follow up of workers in hospitals and some factories or in the setting of routine preoperative, pre-blood donation and pre-traveling evaluation [1] .
Elevation of liver transaminases of unknown etiology is defined as elevation of ALT and/or AST in a non-alcoholic patient in the absence of positive viral markers (HBs antigen and HCV antibody), absence of immune markers (ANA), absence of drug history of an essentially or a potentially hepatotoxic medication, absence of clinical and sonographic criteria of fatty liver disease and absence of family history of liver disease [2] .
In the life cycle of HCV, acute hepatitis C is defined as the first 2 months of HCV infection. In this period of time, the patient is mostly asymptomatic or may complain of non-specific abdominal discomfort or non-specific fatigue. Also in this period of time, liver enzymes may or may not become elevated [3] .
Prevalence of HCV infection is variable throughout the world. In the USA, 1.8 percent of the population is positive for HCV antibodies. Given that 3 of every 4 seropositive persons also have viremia as assessed by the currently available HCV RNA PCR tests, an estimated 2.7 million people in the USA have active HCV infection [4] .
Egypt possibly carries the highest HCV prevalence worldwide with approximately 30-35% of the general population infected [5] . HCV is considered the most common etiology of chronic liver disease in Egypt where prevalence of antibodies to HCV is 10 folds that in the USA and Europe. Approximately 90% of Egyptian HCV isolates belong to genotype 4a [6] .
Early published results that identified HCV viral antigen in the serum of HCV infected patients were reported in 1992. One pioneering study indicated that circulating HCV core antigen could be detected through an enzyme-linked immunosorbent assay (ELISA) sandwich antigen test [7] . In 1995, it was demonstrated that HCV core antigen could be detected and quantified in serum through a simple fluorescent enzyme immunoassay. This procedure required a precipitation step followed by solubilization of the pellet both to reveal the HCV core antigen and to destroy antibodies that may prevent detection of HCV core protein. The processed sample could then be tested for HCV core antigen [8].
There have been multiple studies indicating the potential utility of HCV core antigen testing in three different types of situations; first, to identify HCV infection in the pre-seroconversion window period [9] , second, to distinguish actively infected HCV seropositive individuals from those who have resolved HCV infection [10] and third, to monitor the efficacy of antiviral therapy using a quantitative HCV core antigen assay [11] .
The aim of the present study is to evaluate the clinical utility of HCV core antigen testing in detection of HCV antibody negative HCV infection in patients with asymptomatic elevation of liver transaminases of unknown etiology.
PATIENTS AND METHODS
This study was carried out on 110 asymptomatic patients with elevated liver transaminases. Patients were recruited from the outpatient clinic of Tropical Medicine Department, Zagazig University Hospitals and the HCV treatment center at Al Ahrar hospital in the period from April 2015 to February 2017.
Patients with elevated liver transaminases were divided into two groups; group A which included 55 patients with negative HCV antibody and no identifiable cause of liver transaminase elevation and group B which included 55 patients with positive HCV antibody. Group A patients were recruited from the outpatient clinic of Tropical Medicine Department, Zagazig University hospitals. They accidentally discovered liver transaminase elevation in the setting of routine or periodic self-health screening, routine follow up of workers in hospitals and some factories or in the setting of routine preoperative, pre-blood donation and pre-traveling evaluation. Group B patients were recruited from Al Ahrar HCV treatment center.
HBs antigen positivity, alcoholism, hepatotoxic drug use, ANA positivity, BMI more than 35, sonographically bright fatty liver and hepatocellular carcinoma excluded patients from both groups. Sonographically cirrhotic liver did not exclude patients from either groups. All patients gave a written consent to be included in the study.
All patients were subjected to full history taking and thorough clinical examination. Routine laboratory investigations in the form of CBC and LFT were done for all patients. HBs antigen and ANA were done for all patients ascertain negativity in all patients. HCV antibody by ELISA, HCV core antigen by a prototype ELISA and quantitative HCV RNA PCR were done for all patients. HCV antibody testing was repeated after 6 weeks for HCV infected patients who are initially HCV antibody negative prior to receiving antiviral treatment. Pelviabdominal ultrasound was done for all patients by the same operator.
HCV core antigen detection was performed using a prototype ELISA. This sandwich assay utilizes microwells coated with monoclonal antibodies which recognize HCV core antigen. The conjugate comprised of anti-HCV core antigen monoclonal antibodies labeled with horseradish peroxidase and had different epitope specificity than the antibodies coated onto the solid phase [12] .
Obtained data were collected, tabulated and statistically analyzed using SPSS 22.0 for windows (SPSS Inc., Chicago, IL, USA) and MedCalc 13 for windows (MedCalc Software bvba, Ostend, Belgium). Continuous quantitative variables were expressed as the mean ± SD and median (range) and categorical qualitative variables were expressed as an absolute frequency (number) and a relative frequency (percentage). Continuous data were checked for normality using Shapiro Walk test. Independent samples Student's t-test was used to compare two groups of normally distributed data while Mann-Whitney U test was used for non-normally distributed data. Categorical data were compared using Chi-square test or Fisher's exact test when appropriate. All tests were two sided. P-value <0.05 was considered statistically significant (S), p-value <0.001 was considered statistically highly significant (HS) and p-value ≥ 0.05 was considered statistically non-significant (NS). In the present study, we adopted the method described by Fabrizi et al.
RESULTS
[12] for detecting HCV core antigen and compared it with the gold standard HCV RNA PCR testing in detection of HCV antibody negative HCV infected asymptomtic patients with elevated liver transaminases of unknown etiology.
The present study was carried out at the outpatient clinic of Tropical Medicine Department, Zagazig University where HCV antibody negative patients with elevated liver transaminases of unknown etiology were recruited and the HCV treatment center at Al-Ahrar hospital where HCV antibody positive patients with elevated liver transaminases coming for HCV treatment were recruited. The study was carried out in the period from April 2015 to February 2017.
Patients were divided into 2 groups; group A which included 55 HCV antibody negative patients with elevated liver transaminases of unknown etiology as the case group and group B which included 55 HCV antibody positive patients with elevated liver transaminases as the control group. HBs antigen positivity, alcoholism, hepatotoxic drug use, ANA positivity, BMI more than 35, sonographically bright fatty liver and hepatocellular carcinoma excluded patients from both groups. Sonographically cirrhotic liver did not exclude patients from either groups.
All patients were subjected to full history taking, thorough clinical examination, routine laboratory investigations in the form of CBC and LFT and pelviabdominal ultrasonogrphy performed by the same operator. HBs antigen and ANA were done for all patients ascertain negativity in all patients. HCV antibody by a prototype ELISA, HCV core antigen by a prototype ELISA and the gold standard quantitative HCV RNA PCR were done for all patients. HCV antibody testing was repeated after 6 weeks for HCV infected patients who are initially HCV antibody negative prior to receiving antiviral treatment. Obtained data were compared using appropriate statistical methods.
In this study, the mean age of HCV antibody negative patients was 41. There was no statistically significant difference between both groups as regard age, sex and BMI. This reflects that we tried to match patients in both groups as regard age and sex as well as we intentionally execluded patients with BMI more than 35 to eliminate the possibility of fatty liver disease in both groups.
In the present study, there was no statistically significant difference between both groups as regard liver function tests. This reflects that we intentionally selected asymptomatic patients with isolated elevation of liver transaminases in both groups. As regard CBC, there was a statistically significant difference in hemoglobin level and platelet count between both groups. This reflects that we did not execlude cirrhotic patients from either group and reflects that the prevalence of HCV induced liver cirrhosis is much more common that of cryptogenic cirrhosis. As regard HCV markers, group A patients initially were all HCV antibody negative while group B patients were all HCV antibody positive. 5 patients in group A turned out to have HCV infection as confirmed by HCV RNA PCR testing. 4 out of these 5 patients were positive for HCV core antigen. 8 patients in group B turned out to be free of HCV infection as confirmed by HCV RNA PCR testing. All of these 8 patients were negative for HCV core antigen. 44 out the 47 HCV antibody positive HCV infected patients in group B were positive for HCV core antigen while the rest 3 patients were negative for HCV core antigen.
In this study, there was a statistically highly significant relation between HCV core antigen positivity and negativity and HCV RNA PCR positivity and negativity respectively in HCV 
